Sahin Aysegul A, Guray Merih, Hunt Kelly K
Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Arch Pathol Lab Med. 2009 Jun;133(6):869-78. doi: 10.5858/133.6.869.
The presence or absence of metastases in axillary lymph nodes is one of the most important prognostic factors for patients with breast cancer. During the past decade sentinel lymph node (SLN) biopsy has been increasingly adopted as a minimally invasive staging alternative to complete axillary node dissection.
Sentinel lymph nodes are more likely to contain metastases than non-SLNs. In routine clinical practice SLNs are assessed by diverse methodologies including multiple sectioning, immunohistochemical staining, and molecular diagnostic tests. Despite the lack of standard histopathologic protocols during the years detailed evaluation of SLNs has resulted in an increased detection of small (micro) metastases.
Breast cancer with micrometastases constitutes a heterogenous group of tumors with variable clinical outcome regarding the risk of additional metastases in the remaining axillary lymph nodes and to patients' survival.
The clinical significance of micrometastases has been subject to great controversy in patients with breast cancer. In this review we highlight controversies regarding micrometastases especially in relation to SLNs.
腋窝淋巴结有无转移是乳腺癌患者最重要的预后因素之一。在过去十年中,前哨淋巴结(SLN)活检作为一种微创分期方法,越来越多地被采用,以替代完整的腋窝淋巴结清扫术。
前哨淋巴结比非前哨淋巴结更有可能含有转移灶。在常规临床实践中,前哨淋巴结通过多种方法进行评估,包括多切片、免疫组织化学染色和分子诊断测试。尽管多年来缺乏标准的组织病理学方案,但对前哨淋巴结的详细评估已导致小(微)转移灶的检出率增加。
伴有微转移的乳腺癌构成了一组异质性肿瘤,其在剩余腋窝淋巴结中发生额外转移的风险以及对患者生存的影响具有不同的临床结局。
微转移在乳腺癌患者中的临床意义一直存在很大争议。在本综述中,我们重点强调了关于微转移的争议,特别是与前哨淋巴结相关的争议。